Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Interest Expenses (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Interest Expenses data on record, last reported at $2.6 million in Q3 2025.

  • For Q3 2025, Interest Expenses rose 26.01% year-over-year to $2.6 million; the TTM value through Sep 2025 reached $8.5 million, up 30.92%, while the annual FY2024 figure was $7.8 million, 48.2% up from the prior year.
  • Interest Expenses reached $2.6 million in Q3 2025 per NWBO's latest filing, up from $1.8 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $2.6 million in Q3 2025 and bottomed at $807000.0 in Q2 2021.
  • Average Interest Expenses over 5 years is $1.6 million, with a median of $1.5 million recorded in 2024.
  • The widest YoY moves for Interest Expenses: up 131.52% in 2021, down 71.05% in 2021.
  • A 5-year view of Interest Expenses shows it stood at $1.2 million in 2021, then rose by 5.9% to $1.2 million in 2022, then rose by 1.72% to $1.2 million in 2023, then skyrocketed by 100.32% to $2.5 million in 2024, then rose by 5.35% to $2.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $2.6 million in Q3 2025, $1.8 million in Q2 2025, and $1.6 million in Q1 2025.